Anthony Cedrone, MD
Interventional Cardiology · Castle Rock, CONPI 1194987164
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,143 of the $10,426 with a category attached, or 87.7%. 26 manufacturers reported payments, led by Shockwave Medical, Inc at 27.6% of the total. Reporting peaked in 2023 at $2,866 and has fallen 54.7% since, to $1,299 in 2025.
Across 228 payments — averaging $45.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$3K
- Medtronic$2K
- Boston Scientific$2K
- Asahi Intecc USA, Inc.$681
- Amgen$389
- Novartis$301
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,03410%
- Food & beverage$9,14388%
- Education$991%
- Entertainment$1501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 59 | $2,880 |
| Medtronic(2 entities) | 34 | $2,127 |
| Boston Scientific | 24 | $2,090 |
| Asahi Intecc USA, Inc. | 15 | $681 |
| Amgen | 23 | $389 |
| Novartis | 10 | $301 |
| AstraZeneca | 4 | $280 |
| W. L. Gore & Associates, Inc. | 4 | $200 |
| Abbott | 8 | $184 |
| Impulse Dynamics (USA) Inc. | 1 | $172 |
| Cvrx, Inc. | 1 | $165 |
| Shimadzu Precision Instruments, Inc. | 1 | $150 |
| Abiomed | 13 | $147 |
| Bristol Myers Squibb | 4 | $92 |
| Pfizer | 5 | $88 |
| Cardiva Medical, Inc. | 2 | $82 |
| Boehringer Ingelheim | 3 | $63 |
| Merck | 3 | $54 |
| Heartflow, Inc. | 2 | $51 |
| Johnson & Johnson | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Philips North America LLC | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Terumo Medical Corporation | 1 | $22 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$997
- RESOLUTE ONYX$787
- GENERAL - THERAPIES$605
- OPTIMIZER$344
- SYMPLICITY G3$292
- Onyx$280
- ASAHI PTCA Guide Wire$234
- Vascular Lithotripsy$176
- HawkOne$165
- Barostim Neo System$165
- GORE TAG Conformable Thoracic Endoprosthesis$155
- TRINIAS$150
- STINGRAY$150
- GENERAL VASCULAR ACCESS$150
- GENERAL TACHY$147
- FARXIGA$134
- Asahi Coronary Wires$114
- CROSSBOSS$110
- ELUVIA$106
How this compares
$10,426 in reported general payments places this provider in the 60th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 256 | $323,431 |
| Repatha SureclickEvolocumab | 125 | $117,917 |
| EntrestoSacubitril/Valsartan | 56 | $91,282 |
| JardianceEmpagliflozin | 27 | $44,294 |
| Praluent PenAlirocumab | 30 | $25,639 |
| XareltoRivaroxaban | 13 | $19,783 |
| VascepaIcosapent Ethyl | 19 | $13,733 |
| Repatha SyringeEvolocumab | 11 | $9,249 |
| Rosuvastatin Calcium | 424 | $5,488 |
| Metoprolol Succinate | 464 | $5,171 |
| Atorvastatin Calcium | 377 | $3,137 |
| Ezetimibe | 185 | $3,066 |
| Prasugrel Hcl | 42 | $2,964 |
| Valsartan | 93 | $2,884 |
| ClopidogrelClopidogrel Bisulfate | 245 | $2,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $323,431256 claims |
| NovartisEntresto | $301 | $91,28256 claims |
| Boehringer IngelheimJardiance | $63 | $44,29427 claims |
| Johnson & JohnsonXarelto | $49 | $19,78313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Castle Rock
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
- Jeffrey ParkAurora$132K
- Qaisar KhanThornton$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.